Coagulation Factor XI Market Report – Pipeline Review, H2 2017

“The Latest Research Report Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. – MarketResearchReports.biz”

About Coagulation Factor XI Market

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) pipeline Target constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Coagulation Factor XI-Pipeline Review, H2 2017, outlays comprehensive information on the Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 5 and 6 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Cardiovascular, Hematological Disorders and Infectious Disease which include indications Thrombosis, Bleeding And Clotting Disorders, Arterial Thrombosis, Sepsis, Venous (Vein) Thrombosis, Venous Thromboembolism, Acute Ischemic Stroke, Bacterial Sepsis, Hemophilia C (Factor XI Deficiency), Ischemic Stroke and Stroke.

Request For Sample Report @ https://www.marketresearchreports.biz/sample/sample/1339579

Furthermore, this report also reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

– The report reviews Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics and enlists all their major and minor projects

– The report assesses Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) targeted therapeutics

View Sample PDF @ https://www.marketresearchreports.biz/reports/1339579/coagulation-factor-xi-plasma-thromboplastin-antecedent-or-f11-or-ec-342127-pipeline-review-h2-2017-market-research-reports.pdf

Reasons to buy

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand the targeted therapy areas and indications for Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)

– Identify the use of drugs for target identification and drug repurposing

– Identify potential new clients or partners in the target demographic

– Develop strategic initiatives by understanding the focus areas of leading companies

– Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27) development landscape

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Overview 7

Coagulation Factor

Have Any Query? Ask Our Expert @ https://www.marketresearchreports.biz/sample/enquiry/1339579

XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Therapeutics Development 8

Products under Development by Stage of Development 8

Products under Development by Therapy Area 9

Products under Development by Indication 10

Products under Development by Companies 11

Products under Development by Universities/Institutes 13

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Therapeutics Assessment 15

Assessment by Mechanism of Action 15

Assessment by Route of Administration 17

Assessment by Molecule Type 19

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Companies Involved in Therapeutics Development 21

Bayer AG 21

Bristol-Myers Squibb Co 21

Ionis Pharmaceuticals Inc 22

Mochida Pharmaceutical Co Ltd 22

Novartis AG 23

Coagulation Factor XI (Plasma Thromboplastin Antecedent or F11 or EC 3.4.21.27)-Drug Profiles 24

AB-012-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

AB-022-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

BAY-1213790-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

BMS-262084-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

BMS-654457-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

BMS-962212-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

coagulation factor XI (human)-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

coagulation factor XI (human)-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

EP-7041-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

IONIS-FXILRx-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

IONIS-FXIRx-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Ir-CPI-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

MAA-868-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

MR-1007-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074

Website: http://www.marketresearchreports.biz/

Email: sales@marketresearchreports.biz

Leave a Reply

Designed by CyFocus.com
Powered by CyFocus.net